Biomarkers in the development of novel medicines for the treatment of cancer

European Pharmaceutical Review

Volumn , Issue 3, 2010, Pages

  Winkler, Hans ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOCHEMISTRY; MAXIMUM TOLERATED DOSE; MODEL; NONHUMAN; PHARMACOGENETICS; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; TOXICITY TESTING; TUMOR BIOPSY;

EID: 77954351663     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Collins, I. & Workman, P (2006) New approaches to molecular cancer therapeutics. Nature Chemical Biology 2: 689-700 (Pubitemid 44764211)
2. Hughes, B. (2009) 2008 FDA drug approvals. Nature Reviews Drug Discovery 8: 93-96
3. Paul, S.M., et al. (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Review Drug Discovery 9: 203-214
4. Yamazaki S. et al (2008) Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models. Drug Metabolism Disposition 36:1267-1274 (Pubitemid 351929310)
5. Hunsberger, S. et al. (2005) Dose escalation trial designs based on a molecularly targeted endpoint. Statistics in Medicine 24: 2171-2181 (Pubitemid 40960214)
6. Korn E.L. & Simon, R. (1993) Using the tolerable dose diagram in the design of phase I combination chemotherapy trials. Journal of Clinical Oncology 11:794-801
7. Hall, B., (2009) A new age in drug development: biomarkers and the tumour microenvironment. European Pharmaceutical Review, 1: 38-41
8. Hirsch F.R et al., (2007) Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology 18: 752-760
9. Schilsky R. L., (2010) Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery 9: 363-366